CAS: 1700693-08-8

JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).

JH-II-127

Applications JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor. References Hatcher, J.M.; et al.: ACS Med. Chem. Lett., 6, 584 (2015)

JH-II-127 is a small molecule that activates autophagy by inhibiting the function of the mammalian target of rapamycin (mTOR) complex 1. Autophagy is an evolutionarily conserved process that plays a crucial role in the degradation and recycling of long-lived proteins and organelles. JH-II-127 has been shown to activate autophagy in cancer cells, and may be used as a potential therapy for cancer. JH-II-127 also has anti-inflammatory properties, which could be useful in treating opportunistic infections due to its ability to inhibit nuclear factor kappa B (NFκB).